We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

226 hedge funds and large institutions have $4.34B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 15

325% more call options, than puts

Call options by funds: $160M | Put options by funds: $37.7M

122% more capital invested

Capital invested by funds: $1.95B → $4.34B (+$2.39B)

60% more funds holding in top 10

Funds holding in top 10: 1016 (+6)

29% more funds holding

Funds holding: 175226 (+51)

22% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 63

Holders
226
Holders Change
+51
Holders Change %
+29.14%
% of All Funds
4.63%
Holding in Top 10
16
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+60%
% of All Funds
0.33%
New
67
Increased
77
Reduced
63
Closed
15
Calls
$160M
Puts
$37.7M
Net Calls
+$122M
Net Calls Change
+$22M
Name Holding Trade Value Shares
Change
Change in
Stake
Capital International Investors
1
Capital International Investors
California
$439M +$334K +6,280 +0.1%
BlackRock
2
BlackRock
New York
$258M +$13.8M +260,157 +8%
Marshall Wace
3
Marshall Wace
United Kingdom
$183M -$3.3M -61,999 -2%
Stifel Financial
4
Stifel Financial
Missouri
$182M -$18.5M -347,460 -12%
Capital World Investors
5
Capital World Investors
California
$161M +$39.2K +737 +0%
RM
6
RP Management
New York
$154M
Wellington Management Group
7
Wellington Management Group
Massachusetts
$152M -$55.1M -1,034,992 -33%
OIM
8
Oracle Investment Management
Connecticut
$147M +$7.5M +140,957 +8%
EAM
9
Eventide Asset Management
Massachusetts
$130M
State Street
10
State Street
Massachusetts
$129M -$10.9M -205,232 -10%
JP Morgan Chase
11
JP Morgan Chase
New York
$118M +$3.85M +72,409 +5%
Vanguard Group
12
Vanguard Group
Pennsylvania
$110M +$5.87M +110,271 +8%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$98.9M +$29.9M +562,071 +71%
KCM
14
Kingdon Capital Management
New York
$95.2M -$8.54M -160,500 -11%
AllianceBernstein
15
AllianceBernstein
Tennessee
$89.1M -$15.8M -297,282 -20%
APM
16
Avidity Partners Management
Texas
$80.8M +$30M +564,500 +105%
CII
17
Capital International Inc
California
$78.4M +$637K +11,973 +1%
TCM
18
Tang Capital Management
California
$71.7M +$52.2M +980,461 New
Wells Fargo
19
Wells Fargo
California
$64.8M +$29.1M +546,031 +161%
KCM
20
Knoll Capital Management
Florida
$62.1M
Brown Advisory
21
Brown Advisory
Maryland
$62M +$3.6M +67,578 +9%
GPP
22
Great Point Partners
Connecticut
$61.5M +$13.8M +258,995 +45%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$57.9M +$4.87M +91,467 +13%
PC
24
Polar Capital
United Kingdom
$51M -$9.51M -178,672 -20%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$48M +$2.65M +49,845 +8%

BHVN Hedge Fund Activity: Q2 2020 in Review

226 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2020, worth a combined $4.34B — up 122% from $1.95B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new BHVN positions and 15 closed out — a net gain of 52 holders — while 77 added to existing stakes and 63 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $52.2M. The largest seller was Wellington Management Group, cutting an estimated $55.1M.

  • 226 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2020, up from 175 in Q1 2020.
  • Funds reported $4.34B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2020, up 122% quarter-over-quarter.
  • 67 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2020 and 15 closed out, a net change of +52 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2020 was Tang Capital Management, an estimated $52.2M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2020 was Wellington Management Group, an estimated $55.1M sold.

Based on aggregated 13F filings for Q2 2020.